Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.66 |
| ▸ | HTR2C | P28335 | 5/20 | 0.63 |
| ▸ | HTR1A | P08908 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18197060 | 0.94 | ACHE (0.64) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL18197061 | 0.94 | ACHE (0.64) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL18197095 | 0.94 | ACHE (0.64) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL18194790 | 0.93 | ACHE (0.56) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL18194791 | 0.93 | ACHE (0.56) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL6523805 | 0.85 | ACHE (0.71) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL6523807 | 0.85 | ACHE (0.71) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL6523816 | 0.85 | ACHE (0.71) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL16351781 | 0.78 | ACHE (0.60) | ACHEHTR2CHTR1AMAPTCYP2D6 | |
| SCHEMBL16351775 | 0.78 | ACHE (0.60) | ACHEHTR2CHTR1AMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | ACHE 289/4885HTR2C 981/4885HTR1A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.